5nance5nance
5nance5nance
HomeScreens
LOGINGET FREE ACCOUNT

Glenmark Pharmaceuticals Ltd.

•
glenmarkpharma.comBSE: 532296NSE: GLENMARK
Market Cap₹ 68,211 Cr.
Current Price
High / Low₹ 2,538 / 1,793
Stock P/E37.9
Book Value₹ 388
Price to Book5.75
Dividend Yield0.10 %
ROCE20.4 %
ROE14.1 %
Face Value₹ 1

Add ratio to table

ABOUT

AI Sector View

AI GENERATED

Healthcare

Buy

This stance relies on proxies and positioning because no direct pharma-export or healthcare operating series exists in the dataset. The depreciated currency at 95.23 (Sep/26) can support export earnings, inflation at 4.45% (Jul/26) is manageable for a defensive sector, and consumer spending remains large at INR 44743 billion (Jun/26). Strong FPI inflow of INR 10620 crore over 3 months to 2026-08-31 from INR -11381 crore in the prior 3 months adds a real sector-specific tailwind, but confidence stays capped because the fundamental drivers are indirect proxies.

Confidence
50%
View full sector analysis →

PROS

  • Company is almost debt free
  • Latest quarter profit grew 927.9% YoY, showing strong momentum
  • Operating margins have improved to 13.2% from 6.8%
  • Strong cash generation - operating cash flow backs reported profits (CFO/PAT 4.07x)
  • Company has a consistent dividend-paying track record
  • Company generates healthy free cash flow

CONS

  • Company has a low return on equity of 1.8% over last 3 years
  • Receivables are growing faster than sales - a possible quality concern
  • Operating cash flow has been negative in recent years
  • Recurring exceptional / one-off items are inflating headline profit
  • Company has delivered a poor profit growth of 7.0% over past five years
  • Stock is trading at 5.7x its book value

* The pros and cons are machine generated based on quantitative rules.

Peer comparison

HealthcareHealthcarePharmaceuticals & Drugs
Part ofNIFTYM150MOMNTM50NIFTY ALPHA 50NIFTY PHARMANIFTY500MOMENTM50NIFTYLARGEMIDCAP250
S.No.Name
1.SUNPHARMA1842.0036.54441957.500.872901.2326.5315299.8810.9819.1128.81
2.DIVISLAB9326.0084.64247576.000.32902.0065.503080.0027.8021.5140.75
3.TORNTPHARM4975.0086.76189233.010.76566.003.284921.0057.3219.2733.81
4.ZYDUSLIFE1119.5024.74111670.550.09990.20-34.908017.0023.9721.3924.54
5.CIPLA1365.0032.72110272.680.95785.55-39.187119.284.1316.0016.73
6.LAURUSLABS1970.3597.37106460.420.10362.07123.942026.3129.1018.2031.50
7.DRREDDY1161.0030.0796906.380.69435.60-69.108099.80-5.2113.7510.63
8.AUROPHARMA1675.4525.9796401.690.241032.0325.229150.3517.4412.7620.54
9.LUPIN2096.0017.3495842.920.861416.9816.018276.8934.2828.8629.59
10.MANKIND2277.0046.0494050.370.04574.0929.124030.5912.8913.2426.30
11.GLENMARK2416.9037.9468210.880.10482.83927.884018.4831.3520.3520.03
12.BIOCON390.95128.6363712.890.13136.8053.364336.0010.893.2619.54
Detailed Comparison with:

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
2,9983,1612,4603,0163,2233,4003,3023,2203,0596,0043,8883,7604,018
2,5992,7452,7152,5592,6562,8322,7872,6952,6843,6873,0313,0083,441
Operating Profit400416-2554575675695155253752,316857752578
OPM %13.33%13.15%-10.37%15.17%17.60%16.72%15.58%16.30%12.27%38.58%22.05%20.01%14.37%
-32-324-31326313931-361-297-1,184-140-18466
Interest112121134149404852675866414354
Depreciation142141147151118120123125130141154148173
Profit before Tax151-124-521531462473456896967534388643
Tax %75.12%-44.99%13.77%333.34%26.41%24.99%23.73%45.04%50.86%36.90%24.49%22.29%24.96%
Net Profit0000340354348447610403301483
0.51-7.11-16.66-44.0412.0612.5512.330.161.6621.6314.2910.6817.11

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
9,1869,1039,86510,64110,94412,30511,58311,81313,32216,98317,671
7,1497,4888,2808,9438,8609,9859,94810,61810,97012,41013,167
Operating Profit2,0371,6151,5861,6982,0842,3201,6351,1952,3514,5724,504
OPM %22.17%17.75%16.07%15.96%19.05%18.86%14.12%10.12%17.65%26.92%25.49%
-449137519295-94-477-61-259-1,805-1,443
Interest237286335377353298349516207209204
Depreciation264302326417444487569582486573617
Profit before Tax1,4911,1191,3011,0961,3821,441240361,3991,9852,533
Tax %25.66%28.18%28.88%29.20%29.83%31.06%137.34%5116.71%25.16%31.38%29.01%
Net Profit1,109804925776970994-90-1,8311,0471,3621,798
EPS39.2828.4932.7827.5034.3833.3710.53-53.2137.1148.26—
Dividend Payout %5.09%7.02%6.10%9.09%7.27%7.49%23.73%-4.70%6.74%5.18%—

COMPOUNDED SALES GROWTH

10 Years:
8%
5 Years:
9%
3 Years:
14%

COMPOUNDED PROFIT GROWTH

10 Years:
6%
5 Years:
7%
3 Years:
66%

STOCK PRICE CAGR

10 Years:
11%
5 Years:
36%
3 Years:
44%
1 Year:
14%

RETURN ON EQUITY

10 Years:
11%
5 Years:
3%
3 Years:
2%
Last Year:
14%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Corporate actions

2026

Aug 31

₹ 2.50

Rs.2.5000 per share(250%)Final Dividend

2025

Oct 3

₹ 2.50

Interim Dividend

2025

Sep 15

₹ 2.50

Rs.2.5000 per share(250%)Final Dividend

2024

Sep 13

₹ 2.50

Rs.2.5000 per share(250%)Final Dividend

2023

Sep 18

₹ 2.50

Rs.2.5000 per share(250%)Final Dividend

2022

Sep 12

₹ 2.50

Rs.2.5000 per share(250%)Final Dividend

2021

Sep 8

₹ 2.50

Rs.2.5000 per share(250%)Final Dividend

2018

Sep 19

₹ 2

Rs.2.0000 per share(200%)Dividend

2017

Sep 20

₹ 2

Rs.2.0000 per share(200%)Dividend

2016

Aug 3

₹ 2

Rs.2.0000 per share(200%)Dividend

2015

Sep 10

₹ 2

Rs.2.0000 per share(200%)Dividend

2026

Jul 31

₹ 2.50

Rs.2.5000 per share(250%)Final Dividend

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital28282828282828282828
Minority Interest-0-0-0-0-0351365-0-0-0
4,4635,1255,5666,0297,0159,0429,4287,8018,81210,450
4,7564,4393,9664,9154,8233,2944,7771,5262,8562,842
Trade Payables1,7431,8702,2212,1262,2382,2892,0002,5363,0513,744
-538-187125132-343929671,4181781,598
Total Liabilities10,45311,27511,90613,22914,06915,39717,56613,30914,92518,661
2,7553,0303,6705,0295,1295,8875,4224,2104,4875,915
Capital Work in Progress6309931,2341,0911,2189211,066419542428
161530252550457905642
2,1392,0312,2522,1362,2772,5002,3742,5133,0293,431
00000001,8583,3424,963
Cash & Bank1,0581,2359381,1111,1391,4121,1601,6591,7051,176
3,8563,9723,7823,8384,2824,6287,5001,8591,7652,706
Total Assets10,45311,27511,90613,22914,06915,39717,56613,30914,92518,661

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
1,3562,0001,7671,8591,6411,6671,266-265-8283,445
Cash from Investing-712-1,013-699-784-675-333-5284,5612-1,283
Cash from Financing543-468-739-445-442-520-77-3,906787-2,709
488166-1141641425519389-38-547

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026

Shareholding Pattern

Numbers in percentages

Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
46.6546.6546.6546.6546.6546.6546.6546.6546.65
20.9823.0523.5123.1520.6220.7319.2020.3520.89
13.9213.2113.8514.6017.6418.6120.0919.2818.60
0.040.040.040.040.040.040.040.040.04
18.4117.0615.9615.5615.0613.9714.0213.6813.81

Documents

Corporate disclosures, annual reports, credit ratings, and concall transcripts

2026-09-11
Shareholders meeting

2026-09-11 - Glenmark Pharmaceuticals Limited has informed the Exchange regarding Proceedings of Annual General Meeting held on September 11, 2026. Further, the company has submitted the Exchange a copy of Srutinizers report along with voting results.

2026-09-11
Press Release

2026-09-11 - Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated September 11, 2026, titled "Glenmark Expands Global Respiratory Innovation Footprint with RYALTRIS® Launch in Brazil ".

2026-09-11
Credit Rating

2026-09-11 - Glenmark Pharmaceuticals Limited has informed the Exchange about Credit Rating

2026-08-21
Press Release

2026-08-21 - Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated August 21, 2026, titled "Glenmark Pharmaceuticals Inc., USA launches Calcium Gluconate Injection USP, 1,000 mg/10 mL (100 mg/mL), 5,000 mg/50 mL (100 mg/mL) Single-Dose Vials and 10,000 mg/100 mL (100 mg/mL) Pharmacy Bulk Package".

2026-08-20
Press Release

2026-08-20 - Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated August 20, 2026, titled "Glenmark Pharmaceuticals receives U.S. FDA approval for Fluticasone Propionate Nasal Spray, 0.05 mg (50 mcg)/spray".

2026-08-15
Copy of Newspaper Publication

2026-08-15 - Glenmark Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication

2026-08-13
General Updates

2026-08-13 - Letter to shareholders whose email address are not registered providing the Web Link of Integrated Annual Report

2026-08-13
Shareholders meeting

2026-08-13 - Glenmark Pharmaceuticals Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 11, 2026

2026-08-11
General Updates

2026-08-11 - Settlement Agreement - Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015

News

Recent coverage and analyst commentary for GLENMARK

Loading news…

🤖

AI Stock Analyst

Glenmark Pharmaceuticals Ltd.

🔒

Sign in to Chat with AI

Log in with your 5nance account to ask institutional questions about performance, financials, and outlook.

✨ Sign In to Chat

Free 5nance Account

5nance5nance

Stock analysis and screening tool

5nanceAI © 2020-2026

Made with ❤️ in India.

Data provided by Accord Fintech

Terms & Privacy.

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme

5nance5nance

Product

PremiumWhat's new?Learn

Team

About usSupport

Theme

5nanceAI © 2020-2026

Data provided by Accord Fintech

Made with ❤️ in India.

HomeScreens
Login